Physician profile
Shital Patel
NPI 1225340144
$6,891.11
in general payments reported to CMS, 2019-2025
23 companies · $55.00 in 2025
The $55.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.67 · 2020: $255 · 2021: $175 · 2022: $239 · 2023: $287 · 2024: $5,824 · 2025: $55.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,385 · Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,385.00 |
| Food and Beverage | $781.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,707.85 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $197.89 | 2023 | |
| Urovant Sciences INC | $155.16 | 2022 | |
| Lilly USA, LLC | $147.26 | 2020-2024 | Mounjaro, Jardiance |
| Edwards Lifesciences Corporation | $102.88 | 2020 | |
| Acadia Pharmaceuticals INC | $96.53 | 2021-2025 | Nuplazid |
| Abbvie INC. | $60.53 | 2021-2025 | |
| Dexcom, INC. | $40.85 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.14 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $39.77 | 2022-2023 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $35.95 | 2020 | |
| Boston Scientific Corporation | $34.87 | 2022 | |
| Viiv Healthcare Company | $34.16 | 2020 | |
| Mylan Specialty L.P. | $28.14 | 2019-2020 | |
| Exact Sciences Corporation | $24.07 | 2023 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $22.71 | 2021 | |
| Amarin Pharma, INC. | $21.91 | 2021 | |
| Pfizer INC. | $21.62 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.97 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.37 | 2021 | |
| Cequr Corporation | $15.86 | 2024 | Cequr Simplicity |
| Beta Bionics, INC. | $14.00 | 2024 | Ilet Bionic Pancreas |
| Eisai INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shital Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.